// Biotech and Pharma Therapeutics
GSK delivers in new CEO Miels’ first financial update
February 4, 2026 / gsk-earnings / hiv-respiratory-oncology / pipeline-expansion / new-ceo-miels / drug-approvals-2026
GSK reported strong 2025 financial results under new CEO Luke Miels, driven by HIV, respiratory, and cancer drugs. With key product launches and anticipated approvals, 2026 is positioned as a pivotal year for pipeline execution and revenue growth.
Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates
February 28, 2026 / novartis-pipeline / cancer-drug-development / phase-1-oncology / neurology-therapies / r&d-strategy
Novartis discontinued six early-stage drug programs, mainly in oncology and hematology, while adding two new cancer candidates to its Phase 1 pipeline. The company aims to prioritize high-impact therapies and expand into neurology and neuromuscular diseases.
Boston Scientific continues to see electrophysiology success despite slowdown in growth
February 4, 2026 / pulsed-field-ablation / cardiac-electrophysiology / atrial-fibrillation-treatment / boston-scientific-growth / pfa-market-leadership
Boston Scientific’s electrophysiology sales rose 75% in 2025, driven by pulsed field ablation (PFA), despite recent U.S. market slowdown. The company remains confident in maintaining PFA leadership as global adoption and competition increase.
Digital Health’s Latest Unicorn: Why Investors Are Backing Midi’s Model for Women’s Health
February 4, 2026 / women’s-healthcare / virtual-menopause-care / insurance-covered-telehealth / midlife-wellness-support / midi-health-unicorn
Virtual care startup Midi Health, now valued over $1 billion, offers insurance-covered, ongoing care for women navigating perimenopause, menopause, and broader midlife health needs, addressing a major gap in personalized, accessible women’s healthcare nationwide.
Cancer Detection Startup Secures $4M to Expand Access in Underserved Communities
February 4, 2026 / cancer-screening-access / AI-healthcare-platform / early-cancer-detection / underserved-communities-care / virtual-oncology-services
Cancer detection startup beHuman raised $4M to expand its AI-powered, insurer-covered virtual screening services for multiple cancer types, aiming to improve early detection and access to care in underserved U.S. communities.
// 4th Industrial Revolution
The $25.7B Healthcare Problem AI Is Finally Solving
February 4, 2026 / AI-healthcare-billing / medical-claim-denials / revenue-cycle-management / patient-financial-transparency / provider-burnout-reduction
AI is revolutionizing healthcare billing by automating claim denial resolution, preventing coding errors, and streamlining appeals—reducing provider burnout and improving patient financial transparency in a system that wastes over $25.7B annually fighting denials.
How AI and Predictive Analytics Will Shape EMS, Fire, and Healthcare in 2026
February 3, 2026 / AI-healthcare-2026 / predictive-analytics-EMS / smart-medical-workflows / healthcare-interoperability-tools / emergency-response-technology
In 2026, AI and predictive analytics are transforming EMS, fire, and healthcare by enhancing system coordination, optimizing workflows, and improving real-time decision-making through interoperable, impactful technologies built on responsible innovation.
Contextual errors limit real-world performance of medical AI
February 3, 2026 / medical-AI-context / clinical-AI-errors / AI-healthcare-limits / contextual-AI-challenges / real-world-AI-medicine
Contextual errors—when AI outputs are correct but irrelevant to specific clinical settings—limit the real-world utility of medical AI. Researchers urge improved training data, testing benchmarks, and model architectures to better reflect clinical context and enhance performance.
Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech
January 30, 2026 / Chugai-Pharmaceutical / AI-drug-discovery / antibody-therapy-trial / BRY10-discontinuation / Malexa-platform-AI
Chugai has discontinued BRY10, its only AI-assisted antibody in clinical trials, citing trial data rather than issues with its Malexa AI platform. The company remains committed to expanding AI integration across its drug discovery and development processes.
New proposal aims to secure future of biomedical research in New York
January 29, 2026 / biomedical-research-New-York / clinical-trials-funding / Mount-Sinai-initiative / brain-drain-healthcare / Empire-Biomedical-Research-Institute
Mount Sinai and partners have proposed the Empire Biomedical Research Institute to secure New York’s biomedical future amid federal funding shifts, aiming to protect early-stage research, prevent brain drain, and strengthen the state’s clinical trial and biotech ecosystem.
// Business & Markets
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Feburary 4, 2026 / Zepbound / Mounjaro / GLP-1-therapy / Eli-Lilly-earnings / obesity-diabetes-market
Eli Lilly exceeded Q4 earnings expectations and raised its 2026 outlook, driven by surging demand for GLP-1 drugs Zepbound (for weight loss) and Mounjaro (for diabetes), reinforcing its market leadership over rival Novo Nordisk.
BARDA launches $100M competition to spur antivirals innovation
Feburary 4, 2026 / BARDA / antiviral-development / SMART-Prize / dengue-Zika-treatment / Flaviviridae-Togaviridae
BARDA has launched the $100M SMART Antiviral Prize to accelerate development of broad-spectrum antivirals targeting Togaviridae and Flaviviridae viruses, such as dengue, Zika, West Nile, and Chikungunya, aiming to boost outbreak preparedness and national health security.
Binnopharm links up with Mabwell to launch joint production of MAb in Russia
February 4, 2025 / Binnopharm / Mabwell / dupilumab / asthma-treatment / atopic-dermatitis-Russia
Binnopharm and China’s Mabwell will localize production of a monoclonal antibody drug for asthma and atopic dermatitis in Russia, aiming to reduce reliance on imported Dupixent (dupilumab), currently supplied by Sanofi.
Forecast-topping Lilly leaves Novo Nordisk in the shade
February 4, 2026 / Eli-Lilly / diabetes-treatment / obesity-drugs / Q4-earnings / pharma-forecast
Eli Lilly’s strong Q4 2025 results and 2026 outlook, driven by obesity and diabetes drug sales, significantly outperformed expectations, contrasting sharply with Novo Nordisk’s weaker performance and resulting market decline.
Insulin resistance market tipped for steady expansion to 2036
February 4, 2026 / insulin-resistance / GLP-1-therapies / type-2-diabetes / obesity-treatment / cardiometabolic-health
Insulin resistance treatment is projected to grow steadily through 2036, driven by rising obesity, type 2 diabetes rates, and increased use of GLP-1 therapies like semaglutide and tirzepatide to improve insulin sensitivity.
// Legal & Regulatory
Medtronic to acquire CathWorks for up to $585M
February 28, 2026 / Medtronic / coronary-disease / FFRangio-system / cardiac-imaging / AI-diagnostics
Medtronic will acquire CathWorks for up to $585M to enhance coronary artery disease diagnostics. CathWorks’ AI-driven FFRangio System offers real-time, non-invasive coronary flow assessments, supporting accurate revascularization decisions during angiography procedures.
States widen generics antitrust case to Novartis in new filing
February 4, 2026 / Novartis / Sandoz / generic-drug-pricing / antitrust-lawsuit / biosimilars
Novartis and former generics unit Sandoz face expanded antitrust litigation from 42 US states over alleged price-fixing and market allocation of generic drugs, potentially impacting access to affordable medications and future biosimilar market dynamics.
Abbott receives FDA warning letter over Freestyle Libre CGMs
February 3, 2026 / Abbott / FreeStyle Libre / FDA-warning-letter / glucose-monitoring / device-accuracy
The FDA issued a warning letter to Abbott over performance and accuracy testing concerns for its FreeStyle Libre continuous glucose monitors. Abbott is implementing corrective actions; product distribution and marketing remain unaffected.
Relay Thera’s zovegalisib wins ‘Breakthrough’ status from FDA
February 3, 2025 / Relay-Therapeutics / zovegalisib / breast-cancer / PIK3CA-mutation / FDA-designation
Relay Therapeutics’ zovegalisib received FDA Breakthrough Therapy designation for use with fulvestrant in treating PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6 inhibitor failure, addressing a major unmet need in recurrent or progressive disease.
FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases
February 3, 2026 / CAR-T / autoimmune-disease / FDA-guidance / Kyverna-Therapeutics / long-term-safety
The FDA plans a flexible, case-by-case regulatory approach for CAR-T therapies in autoimmune diseases, balancing their remission potential with long-term safety concerns, such as fertility effects and secondary malignancies, as therapies like Kyverna’s miv-cel approach approval.
// Research & Development
A 25-year study found an unexpected link between cheese and dementia
February 4, 2026 / cheese-consumption / dementia-risk / full-fat-dairy / Alzheimer’s-prevention / brain-health
A 25-year Swedish study found that higher intake of full-fat cheese and cream was linked to reduced dementia risk in adults without genetic predisposition to Alzheimer’s, challenging longstanding low-fat dietary guidelines.
Amgen advances toward lupus redemption while gastric cancer candidate struggles
February 4, 2026 / daxdilimab / discoid-lupus / autoimmune-treatment / Amgen-pipeline / bemarituzumab-gastric-cancer
Amgen’s daxdilimab met its primary endpoint in a phase 2 trial for discoid lupus, showing reduced disease severity and acceptable safety, marking progress after past lupus failures. Meanwhile, gastric cancer candidate bemarituzumab is being dropped due to limited efficacy.
Brain computer interfaces decode imagined speech in paralyzed patients
February 4, 2025 / brain-computer-interface / imagined-speech / ALS-communication / neural-decoding / assistive-neurotechnology
Researchers used brain-computer interfaces to decode imagined speech in paralyzed patients, distinguishing intentional communication from inner thoughts. This AI-powered advance may restore language abilities in people with conditions like ALS by interpreting brain signals via implanted devices.
Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq
February 4, 2025 / stem-cell-therapy / acute-liver-injury / regenerative-medicine / SPAC-merger / mesenchymal-stem-cells
PrimeGen US is going public via SPAC merger to fund development of its triple-activated mesenchymal stem cell therapies, targeting acute liver injury and related diseases. The biotech aims to begin clinical trials following preclinical success and FDA engagement.
Genetic testing takes greater share of Medicare Part B test spending: OIG
February 4, 2025 / Medicare Part B / genetic testing trends / OIG lab spending / PAMA reimbursement / cancer screening diagnostics
Genetic testing accounted for 43% of Medicare Part B lab spending in 2024, up from 18% in 2018, driven by cancer and pathogen testing, despite fewer beneficiaries receiving tests overall, per the OIG’s annual review under PAMA.
// Politics
Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
February 4, 2026 / telehealth extension / PBM reform Medicare / hospital-at-home program / Medicaid DSH delay / healthcare transparency legislation
New legislation restores Medicare telehealth and hospital-at-home flexibilities, extends reimbursement policies, delays Medicaid DSH cuts, and enacts PBM reforms to increase pricing transparency—key shifts that support care delivery innovation and cost control across U.S. healthcare systems.
Why TrumpRx is stumbling before it gets off the ground
February 4, 2026 / TrumpRx controversy / DTC drug platforms / anti-kickback concerns / pharmaceutical pricing transparency / BlinkRx conflict
TrumpRx, a direct-to-consumer drug platform, faces legal and ethical scrutiny over potential anti-kickback violations, conflicts of interest, and concerns about steering patients toward high-cost drugs without adequate safeguards or transparency, delaying its anticipated launch.
AAM backs funding bill provisions, urges tougher PBM action
February 4, 2026 / generic drug access / PBM reform advocacy / FDA regulatory delays / AAM healthcare savings / pharmaceutical competition policy
AAM supports new U.S. funding bill provisions aimed at accelerating generic drug approvals and reducing regulatory barriers, while urging Congress to take stronger action against PBM practices that limit competition and inflate drug costs.
More America First Fees: US FDA Proposes GDUFA Facility Fee Waiver For Domestic Construction
February 3, 2026 / FDA GDUFA waiver / domestic drug manufacturing / facility fee policy / pharma industry concerns / generics market impact
The FDA proposes waiving GDUFA facility fees for three years to encourage U.S.-based drug manufacturing, but industry voices warn it may unfairly shift financial burden to other sponsors, potentially disrupting market competition.
Trump administration officials blocked FDA effort to fast-track review of psychedelic treatment
February 4, 2026 / psilocybin treatment blocked / FDA priority review / psychedelic depression therapy / Compass Pathways veto / mental health innovation
Trump administration officials blocked the FDA’s attempt to fast-track Compass Pathways’ psilocybin treatment for severe depression, revealing internal resistance to psychedelic therapies despite the drug’s inclusion on a priority review list for innovative mental health treatments.